RESUMO
AIM: The aim of this paper was to evaluate by clinical and non-invasive instrumental evaluations, the efficacy and the tolerance of a cosmetic slimming treatment for menopausal women used topically (for at least 3 years) under dermatological control. METHODS: A controlled double blind, randomised study was performed to compare the slimming efficacy of the cosmetic slimming treatment versus placebo after 4 weeks of treatment. RESULTS: Cosmetic slimming treatment twice a day for 4 weeks reduced abdomen and hips fat, with no significant variation in body weight in comparison with the placebo. CONCLUSION: The present study evidenced the clinical effectiveness and women satisfaction of a slimming treatment specifically studies for postmenopausal adipose tissue with potential interesting consequences on measures of quality of life and on health-care programs.
Assuntos
Tecido Adiposo/cirurgia , Técnicas Cosméticas , Obesidade/cirurgia , Procedimentos de Cirurgia Plástica , Pós-Menopausa , Idoso , Método Duplo-Cego , Feminino , Humanos , Pessoa de Meia-IdadeRESUMO
The presence of high-affinity brain-derived neurotrophic factor receptor Trk B in mouse and in human fetal oocytes, together with the presence of neurotrophins in human follicular fluid suggests a paracrine role for brain-derived neurotrophic factor (BDNF) in female biology. This study aims to evaluate if BDNF is present and quantitatively determined in human menstrual blood and endometrium. Twenty-one women were studied and subdivided in two groups: A, 11 fertile women (27 ± 2 days cycle length) and B, 10 anovulatory women and/or women with inadequate luteal phase (36 ± 2 days cycle length). In fertile women menstrual BDNF levels was higher than plasma (679.3 ± 92.2 vs 301.9 ± 46.7 pg/ml p <0.001). Similarly, in Group B, BDNF in menstrual blood was higher than plasma (386.1 ± 85.2 vs 166.8 ± 24.1 pg/ml p < 0.001). Moreover, both menstrual and plasma BDNF concentrations in Group A were significantly higher respect to Group B (679.3 ± 92.2 vs 386.1 ± 85.2 pg/ml p < 0.001; 301.9 ± 46.7 vs 166.8 ± 24.1 pg/ml p < 0.001). Immunohistochemistry evidence of BDNF in endometrium, during follicular and luteal phase, was also shown. The detection of BDNF in the human menstrual blood and endometrium further supports the role of this neurotrophin in female reproductive function.
Assuntos
Fator Neurotrófico Derivado do Encéfalo/sangue , Fator Neurotrófico Derivado do Encéfalo/metabolismo , Endométrio/metabolismo , Menstruação/sangue , Adulto , Análise Química do Sangue , Fator Neurotrófico Derivado do Encéfalo/isolamento & purificação , Fator Neurotrófico Derivado do Encéfalo/fisiologia , Estudos de Casos e Controles , Endométrio/química , Feminino , Humanos , Fase Luteal/sangue , Ciclo Menstrual/sangue , Plasma/química , Plasma/metabolismo , Progesterona/sangue , Adulto JovemRESUMO
INTRODUCTION: Estetrol (E4), a naturally occurring estrogen only produced by the human fetal liver, is being evaluated in human studies for potential use in contraception and menopausal care. The present study was designed to profile E4 in the central nervous system, to assess the in vivo effects of E4 administration on allopregnanolone (AP) synthesis in specific brain structures and to evaluate whether E4 has synergic or antagonistic effects on estradiol-mediated AP synthesis. MATERIAL AND METHODS: Intact female adult rats received different doses of E4, and ovariectomized OVX rats received different doses of E4 or E2V or combinations of both drugs. The concentrations of AP were assessed in the frontal and parietal cortex, hippocampus, hypothalamus, anterior pituitary, and serum. RESULTS: E4 did not alter AP in intact animals in any region. E4 at a dosage of 5mg/kg/day increased AP levels in different brain areas and in the serum of OVX animals. However, in the presence of estradiol, E4 showed an estrogen-antagonistic effect on the brain and serum levels of AP. CONCLUSION: E4 increases the CNS and peripheral levels of AP, behaving as a weak estrogen-agonist in OVX rats. The antagonistic effect observed with E2V co-administration further profile E4 as a natural SERM.
Assuntos
Biomarcadores/análise , Encéfalo/metabolismo , Estetrol/administração & dosagem , Ovariectomia , Pregnanolona/análise , Animais , Encéfalo/efeitos dos fármacos , Estetrol/farmacologia , Feminino , Radioimunoensaio , Ratos , Ratos WistarRESUMO
Brain-derived neurotrophic factor (BDNF) is a neurotrophin abundantly expressed in several areas of the central nervous system (CNS) and is known to induce a lasting potentiation of synaptic efficacy, to enhance specific learning and memory processes. BDNF is one of the key molecules modulating brain plasticity and it affects cognitive deficit associated with aging and neurodegenerative disease. Several studies have shown an altered BDNF production and secretion in a variety of neurodegenerative diseases like Alzheimer's and Parkinson's diseases but also in mood disorders like depression, eating disorders and schizophrenia. Plasma BDNF is also a biomarker of impaired memory and general cognitive function in aging women. Gonadal steroids are involved in the regulation of several CNS processes, specifically mood, affective and cognitive functions during fertile life and reproductive aging. These observations lead many scientists to investigate a putative co-regulation between BDNF and gonadal and/or adrenal steroids and their relationship with gender difference in the incidence of mental diseases. This overview aims to summarize the current knowledge on the correlation between BDNF expression/function and both gonadal (progesterone, estrogens, and testosterone) and adrenal hormones (mainly cortisol and dehydroepiandrosterone (DHEA)) with relevance in clinical application.